NCT00003934View on ClinicalTrials.gov

Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

November 30, 2006

Conditions
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Promyelocytic Leukemia (M3)Childhood Acute Promyelocytic Leukemia (M3)Untreated Adult Acute Myeloid LeukemiaUntreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
DRUG

tretinoin

Given orally

DRUG

daunorubicin hydrochloride

Given IV

DRUG

cytarabine

Given IV

DRUG

mercaptopurine

Given IV

DRUG

methotrexate

Given IV

DRUG

arsenic trioxide

Given IV

Trial Locations (2)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003934 - Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | Biotech Hunter | Biotech Hunter